Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis

Recruiting Phase 1 Interventional Study
Psychosis Negative Symptoms With Primary Psychotic Disorder
Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 45
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Treatment
Participants needed
46 (estimated)
Sponsor
Bjorn H. Ebdrup · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Antipsychotics affects the brain's dopamine system, and the drugs reduce delusions, hallucinations, and disorganized thinking, which are cardinal symptoms of psychotic disorders. However, negative symptoms e.g. anhedonia, avolition, and social withdrawal, as well as cognitive deficits, are not sufficiently treated. Memantine is used to treat Alzheimer's disease and affects the brain's glutamate s…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patients: * Antipsychotic-free(as defined under Exclusion Criteria below), first episode psychosis * Fulfilling the diagnostic criteria of schizophrenia, persistent delusional disorder, acute and transient psychotic disorders, schizoaffective disorder, other non-organic p…
Contacts

Bjorn H Ebdrup, MD, PhD

+4538640840

bebdrup@cnsr.dk

CONTACT